The Cremins lab investigates the epigenetic mechanisms regulating development and function of the mammalian central nervous system. We map and analyze neuronal epigenomes in three-dimensions using quantitative, genome-wide technologies. We also perturb epigenomes by employing state-of-the art genetic engineering strategies (e.g. CRISPR/Cas9, optoepigenetics). To test our hypotheses, we primarily use embryonic and induced pluripotent stem cell models of neuronal differentiation and disease. Our long-term goal is to discover how genome architecture controls genome function, applying this to study fundamental mechanisms controlling neuronal phenotype and, by extension, the onset and progression of neurodegenerative and neurodevelopmental disease states.

May 19, 2020

Jon Beagan presents at a virtual conference sponsored by Arima alongside
Dan Geschwind and Schahram Akbarian

May 15, 2020

Jon Beagan wins the 2020 Sol Pollack award for the PhD thesis
representing original research at the forefront of its field.

May 12, 2020

Miriam Minsk and Kelly Feng wrap up their junior year after conquering
the challenging Covid-19 virtual semester. Miriam and Kelly – we are so
proud of you.

May 12, 2020

Jennifer gives a virtual seminar at New York University

May 6, 2020

Jennifer speaks on the lab’s work at Cold Spring Harbor Biology of
Genomes virtual meeting

Apr 29, 2020

Jennifer speaks on the lab’s work at Cold Spring Harbor Genome
Organization virtual meeting

Apr 24, 2020

Jenn receives positive news of the NSF CAREER award

Apr 15, 2020

Congratulations to Dr. Thomas Gilgenast PhD on successfully defending
his thesis!

Apr 3, 2020

The lab passes the tenure milestone!

Mar 27, 2020

Congratulations Dan Emerson on his acceptance into Penn Bioengineering’s
PhD program. Welcome to the lab as a PhD student Dan!

logos  

 

Our work is supported by the New York Stem Cell Foundation, the Alfred P. Sloan Foundation, the National Science Foundation, an NIH New Innovator Award through the National Institute of Mental Health and the NIH 4D Nucleome Common Fund Initiative.